Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Werewolf Therapeutics Inc (NQ: HOWL )

5.580 +0.100 (+1.82%)
Streaming Delayed Price Updated: 10:43 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Werewolf Therapeutics Inc

< Previous 1 2 3 4 Next >
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Via Benzinga
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024
HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Recap: Werewolf Therapeutics Q4 Earnings
Via Benzinga
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel... 
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
HOWL stock results show that Werewolf Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Delta Air Lines Layoffs 2023: What to Know About the Latest DAL Job Cuts
Delta Air Lines layoffs have the air travel company announcing minor adjustments to its corporate and management positions. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 Earnings
Carvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report. 
Via InvestorPlace
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. 
Via Benzinga
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
Werewolf Therapeutics stock is taking off with heavy trading of HOWL shares after posting preliminary data from a clinical trial. 
Via InvestorPlace
Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars
Werewolf Therapeutics Inc (NASDAQ: HOWL) released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting... 
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! 
Via InvestorPlace
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.